Lexington diagnostics maker T2 Biosystems' stock plummets on CEO departure, low earnings

Lexington sepsis and lyme disease diagnostics maker T2 Biosystems will need a new CEO to lead it through its ongoing financial struggles. T2 Biosystems (Nasdaq: TTOO) reported after markets closed Tuesday that CEO John McDonough will be stepping down from his role to become executive chairman of the company's board of directors. He will stay in the CEO role until the company hires his successor, according to a press release. McDon ough has been in the top job at T2 since 2007, leading T2 Biosystems…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news